News about "Eli Lilly and Company "

US FDA Grants Breakthrough Therapy Designation to Lilly's Olomorasib for Advanced Pancreatic Cancer

The US FDA has granted Breakthrough Therapy designation to Eli Lilly's investigational KRAS G12C inhibitor, olomorasib, for treating previously treated advanced pancreatic cancer, reinforcing its potential across difficult-to-treat KRAS-driven cancers.

Eli Lilly And Company | 04/08/2026 | By News Bureau

BioArctic and Lilly Sign Collaboration and Research Agreement for BrainTransporter-Based Therapy

BioArctic and Lilly have entered a research and collaboration agreement to combine a Lilly compound with BioArctic’s BrainTransporter technology. BioArctic will receive a USD 30 million upfront payment under the deal.

Eli Lilly And Company | 24/06/2026 | By News Bureau

Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes

Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.

Eli Lilly And Company | 10/06/2026 | By News Bureau |  138

Eli Lilly and Company Launches Lormalzi for Early-Stage Alzheimer's Treatment in India

Eli Lilly and Company India has launched Lormalzi, a once-monthly amyloid-targeting therapy approved for early-stage Alzheimer’s disease, marking a significant advancement in evidence-based treatment options for cognitive decline in India.

Eli Lilly And Company | 14/05/2026 | By News Bureau |  135

Roche Receives CE Mark for Blood-Based Alzheimer's Diagnostic Test

Roche receives CE Mark approval for Elecsys pTau217, a blood-based Alzheimer’s diagnostic test developed with Eli Lilly, aimed at enabling earlier and less invasive detection of amyloid pathology in patients with cognitive decline.

Eli Lilly And Company | 13/05/2026 | By News Bureau

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Eli Lilly And Company | 13/05/2026 | By News Bureau |  158

Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis

Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.

Eli Lilly And Company | 06/05/2026 | By News Bureau |  165

Eli Lilly and Company to Acquire Ajax Therapeutics to Expand Blood Cancer Pipeline

Eli Lilly and Company to acquire Ajax Therapeutics, advancing its blood cancer pipeline with AJ1-11095, a Phase 1 JAK2 inhibitor targeting myelofibrosis and polycythemia vera, with potential for improved disease control.

Eli Lilly And Company | 28/04/2026 | By News Bureau |  131

Amazon Pharmacy to Deliver Foundayo Same-Day, Expanding Access to Eli Lilly's New GLP-1 Pill

Amazon Pharmacy now offers Eli Lilly’s GLP-1 pill Foundayo with real-time availability, transparent pricing from USD 1/day with insurance, USD 5/day cash, and automatic manufacturer-sponsored coupons—soon via in-office kiosks within minutes.

Eli Lilly And Company | 09/04/2026 | By News Bureau |  288

Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration

Fauna Bio has achieved a target designation milestone in its obesity discovery collaboration, advancing a novel target identified through its Convergence AI platform.

Eli Lilly And Company | 20/03/2026 | By News Bureau |  141